Experimental Ebola Drug Seems To Be Curing American Patients
International Business Times
Published Aug 05, 2014 10:20AM ET
Updated Aug 05, 2014 10:45AM ET
Experimental Ebola Drug Seems To Be Curing American Patients
By Meagan Clark - An experimental drug made from tobacco plants appears to be saving two Americans infected with Ebola. The biotechnology drug produced by Mapp Biopharmaceutical Inc., a San Diego-based company with nine employees, had only been tested on infected animals when it was given to the two health workers, Bloomberg reported.
A subsidiary of Reynolds American Inc. NYSE:RAI manufactures the ZMapp drug.
The patients, Christian missionaries Kent Brantly and Nancy Writebol, each received a dose of ZMapp in Liberia before flying to the U.S. for isolated treatment in Atlanta.
Brantly told his doctors in Liberia he was dying July 31, as his breathing became labored on the ninth day of his symptoms. But within an hour of taking the first dose, his condition reversed, causing a doctor to call his recovery "miraculous," according to CNN. In trials, small monkeys were given the drug within 48 hours of infection with Ebola. One monkey not given the drug died on the fifth day of infection.
Brantly arrived at Emory University's hospital Aug. 2. After receiving a second dose of the drug, his condition has continued improving, according to Samaritan Purse, his mission organization. Writebol returned to the U.S. Tuesday in “serious, but stable, condition,” according to her aid organization SIM. She will be given a second dose of the drug upon arrival to Atlanta.
ZMapp hasn't gone through clinincal trials, so its administration to Brantly and Writebol, though with their consent, was highly unusual. Though the drug is not difficult to manufacture, pharmaceutical companies don't have an economic incentive to produce the drug because developing and licensing the drug would be costly, and Ebola has killed only thousands since 1976, mostly poor Africans, health workers told the Telegraph.
Get The News You Want
Written By: International Business Times
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.